• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community

    10/28/25 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CDIO alert in real time by email

    A customized program for YMCA of East Tennessee members will include educational series "Wisdom Wednesdays," and access to Cardio Diagnostics' AI-powered cardiovascular testing at discounted rates from home or during the Heart Health Fair

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Company is partnering with YMCA of East Tennessee to launch a customized program exclusively for its members. Through this program, YMCA members will learn how to take proactive steps to prevent and detect heart disease early while gaining access to Epi+Gen CHD™ and PrecisionCHD™ clinical tests from Cardio Diagnostics at a special discounted rate.

    Heart disease remains the leading cause of death in the United States including in Tennessee, accounting for 22.9% of all deaths statewide, compared with about 20.1% nationally. Tennessee also ranks sixth highest in the nation for cardiovascular mortality, underscoring the need for proactive prevention and early detection.

    The YMCA of East Tennessee has long been a cornerstone of health and wellness for the Knoxville community, serving more than 40,000 members across five locations in the greater Knoxville area, including Tennova, Davis, Cansler, Pilot, and Downtown branches. Through a wide range of programs that promote physical fitness, healthy living, and community engagement, the YMCA continues to add value to the lives of its members and community.

    Building on this commitment, the partnership between YMCA of East Tennessee and Cardio Diagnostics brings an innovative new layer of support for heart health. Together, the two organizations aim to empower individuals to take a proactive approach to cardiovascular wellness by providing education, early detection tools, and actionable insights that can help prevent heart disease before it occurs.

    Beginning in November 2025, Cardio Diagnostics will host six Wisdom Wednesdays educational sessions, taking place on the third Wednesday in November, December, and January at two locations, the YMCA of East Tennessee's Tennova Family and Davis Family branches. The first Wisdom Wednesday will feature Cardio Diagnostics' Chief Medical Officer, Robert Philibert, M.D., Ph.D., focusing on why CHD prevention should matter and the steps individuals can take to begin their heart health journey.

    Concurrently, YMCA of East Tennessee members and the East Tennessee community will have access to Cardio Diagnostics' evidence-based Precision Cardiovascular Medicine clinical tests, Epi+Gen CHD and PrecisionCHD, at a discounted rate. Epi+Gen CHD is a test that assesses the three-year risk for a coronary heart disease (CHD) event, including a heart attack. PrecisionCHD aids in the diagnosis and management of CHD. Both are physician-ordered, epigenetics and AI-based simple blood tests that will be made available through Cardio Diagnostics' telemedicine partner's platform. Individuals will have the option to immediately request an at-home sample collection kit or opt to have their sample collected at the Heart Health Fair in February 2026, which coincides with American Heart Month.

    "We are thrilled to partner with the YMCA of East Tennessee to make cardiovascular prevention and early detection more accessible," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. "By combining education with advanced, AI-driven testing, we are giving individuals the ability to be proactive, to understand, manage, and protect their heart health under the guidance of a physician before serious issues arise."

    "The YMCA of East Tennessee is committed to strengthening our community through programs that promote health and well-being," said Erin Stidham, Executive Director of the Davis Family YMCA. "This partnership with Cardio Diagnostics allows us to offer our members and the broader East Tennessee community access to cutting-edge cardiovascular testing technology that can truly save lives."

    Through this collaboration, the YMCA of East Tennessee and Cardio Diagnostics are committed to extending access beyond YMCA members to the entire East Tennessee community, encouraging individuals and families to take meaningful steps toward a heart-healthy future. For more information about the Wisdom Wednesdays series, reach out to YMCA of East Tennessee's Tennova Family and Davis Family locations. For questions and information on Cardio Diagnostics' tests or the Heart Health Fair, email [email protected].

    About YMCA of East Tennessee

    The Y is one of the nation's leading nonprofits strengthening communities through youth development, healthy living and social responsibility. Across the U.S., 2,700 Ys engage 22 million men, women and children – regardless of age, income or background – to nurture the potential of children and teens, improve the nation's health and well-being, and provide opportunities to give back and support neighbors. Anchored in more than 10,000 communities, the Y has the long-standing relationships and physical presence not just to promise, but to deliver, lasting personal and social change. www.ymcaknoxville.org

    About Cardio Diagnostics

    Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ("Core Technology") for cardiovascular disease. For more information, please visit https://cdio.ai/.

    Forward-Looking Statements

    Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will," "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, and dependence on results as discussed in the Annual Report on Form 10-K for the period ended December 31, 2024, under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251028273603/en/

    Investors

    Investor Relations

    855-226-9991

    [email protected]

    Media & Public Relations

    Public Relations

    855-226-9991

    [email protected]

    Get the next $CDIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CDIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Fung Peter K

    4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    1/6/26 2:20:19 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Director Betts Wendy J

    4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    1/6/26 2:17:11 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Director Intrater James

    4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    1/6/26 2:13:51 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CDIO
    SEC Filings

    View All

    SEC Form 10-K filed by Cardio Diagnostics Holdings Inc.

    10-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

    3/13/26 5:18:52 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

    2/19/26 8:00:30 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.

    10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

    11/12/25 4:30:33 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CDIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Technology Officer Dogan Timur bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

    4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    10/9/24 1:18:30 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: Chief Executive Officer Dogan Meeshanthini bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

    4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    10/8/24 10:42:31 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: Chief Executive Officer Dogan Meeshanthini bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

    4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    10/7/24 11:29:46 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CDIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India

    Agreement expands Cardio Diagnostics' global footprint and supports improved detection and management of coronary heart disease in India. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India's most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories and 300+ MD pathologists in their internal network, today announced a stra

    1/7/26 6:25:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cardio Diagnostics Holdings, Inc. and Southdale YMCA Announce New Heart Health Partnership to Serve the Edina, Minnesota Community

    Southdale YMCA, part of YMCA of the North, becomes the second YMCA location nationally to partner with Cardio Diagnostics, expanding community access to AI-powered cardiovascular testing and education Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced a new partnership with the Southdale YMCA to bring expanded heart health education and advanced cardiovascular testing to their members and the broader Edina community. The Southdale YMCA primarily serves the Edina, Richfield, Bloomington, and South Minneapolis areas, supporting more than 14,000 individuals, approximately 80% of whom are adults. This collaboration build

    1/6/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CDIO
    Financials

    Live finance-specific insights

    View All

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CDIO
    Leadership Updates

    Live Leadership Updates

    View All

    Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the American Heart Association Board of Directors. The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company's continued growth and market expansion. He brings a wealth of experience and proven track record in clinical practice, innovation and research, makin

    1/24/24 8:31:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee. Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity. He is also the CEO of Akan Biosciences, a clinical-stage biotech company, and runs an advisory firm working closely with healthcare growth companies. Mr. Burton brings over 20 years of experience in medical

    12/21/23 9:21:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CDIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cardio Diagnostics Holdings Inc. (Amendment)

    SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)

    5/8/24 2:22:56 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care